Federal Circuit Revives Mutual’s Antitrust Counterclaims Arising From Temazepam ANDA Litigation
In 2006, Mutual filed an ANDA for a generic version of Restoril (temazepam), including a paragraph IV certification to Tyco’s U.S. Patent No. 5,211,954. Tyco filed suit against Mutual under 35 USC 271(e)(2), Mutual responded with antitrust counterclaims (which the court temporarily stayed pending resolution of the case), and the case proceeded to judgment.
To read the full article, click here: http://www.orangebookblog.com/2014/08/federal-circuit-revives-mutuals-antitrust-counterclaims-stemming-from-temazepam-anda-litigation.html